A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.
Related Posts
Stock futures are little changed after S&P 500 clinches record high: Live updates
Investors continue to largely shake off concerns around persistent inflation and tariffs.
Energy drink stock Celsius pops more than 30% on big quarterly results, Alani Nu acquisition
Investors appear reassured by the company’s potential growth prospects, given its record full-year revenue and its acquisition of a rival energy drink brand.
European stocks set for broadly higher open amid more tariff news; BOE and earnings ahead
Join CNBC for live updates on European markets.